Xeris Biopharma director Jeffrey Sherman to retire
Xeris Biopharma Holdings, Inc. reported that Dr. Jeffrey Sherman will retire from its Board of Directors and will not stand for reelection at the 2026 Annual Meeting of Stockholders.
Rhea-AI Filing Summary
Xeris Biopharma Holdings, Inc. reported that Dr. Jeffrey Sherman will retire from its Board of Directors and will not stand for reelection at the 2026 Annual Meeting of Stockholders. He has served as a director since 2021 and sits on the Compensation Committee and the Nominating and Corporate Governance Committee.
The company stated that Dr. Sherman’s decision is not due to any disagreement regarding operations, policies, or practices. When his term ends at the 2026 Annual Meeting, the Board size will be reduced from eight to seven directors.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Notice date: April 20, 2026
Annual Meeting year: 2026
Board size before change: 8 directors
+2 more
5 metrics
Notice date
April 20, 2026
Date Dr. Sherman notified Xeris Biopharma of his decision to retire
Annual Meeting year
2026
Year of the Annual Meeting at which Dr. Sherman’s term will expire
Board size before change
8 directors
Board size before Dr. Sherman’s retirement becomes effective
Board size after change
7 directors
Board size effective upon expiration of Dr. Sherman’s term at the 2026 Annual Meeting
Director tenure start
2021
Year Dr. Sherman began serving as a director of Xeris Biopharma
Key Terms
Board of Directors, Annual Meeting of Stockholders, Compensation Committee, Nominating and Corporate Governance Committee, +1 more
5 terms
Board of Directors financial
"Dr. Jeffrey Sherman, a member of the Board of Directors (the “Board”) of Xeris Biopharma Holdings, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Annual Meeting of Stockholders financial
"not stand for reelection at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)."
Compensation Committee financial
"and is a member of the Compensation Committee and Nominating and Corporate Governance Committee."
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Nominating and Corporate Governance Committee financial
"and is a member of the Compensation Committee and Nominating and Corporate Governance Committee."
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors or Certain Officers;"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What board change did XERS disclose in this 8-K?
Xeris Biopharma Holdings, Inc. disclosed that director Dr. Jeffrey Sherman will retire and not stand for reelection at the 2026 Annual Meeting of Stockholders. His term will end at that meeting, and the Board will then be reduced from eight to seven directors.
Why is Dr. Jeffrey Sherman leaving the XERS Board?
Dr. Jeffrey Sherman notified Xeris Biopharma that he will retire from the Board and not stand for reelection at the 2026 Annual Meeting. The company stated his decision is not due to any disagreement over operations, policies, or practices with management or the Board.
What committees did Dr. Sherman serve on at Xeris Biopharma (XERS)?
Dr. Jeffrey Sherman has served on the Xeris Biopharma Board since 2021 and is a member of the Compensation Committee and the Nominating and Corporate Governance Committee. He will continue in these roles until his Board term expires at the 2026 Annual Meeting of Stockholders.
How will the XERS Board size change after Dr. Sherman’s retirement?
In connection with Dr. Sherman’s retirement, the Xeris Biopharma Board approved reducing its size from eight to seven directors. This change will take effect when his term expires at the 2026 Annual Meeting of Stockholders, aligning the Board size with the remaining directors.
When did Xeris Biopharma receive notice of Dr. Sherman’s retirement?
Xeris Biopharma received notice of Dr. Jeffrey Sherman’s decision to retire from the Board on April 20, 2026. He will continue to serve as a director and committee member until his current term concludes at the company’s 2026 Annual Meeting of Stockholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
